LOS ANGELES, CA / ACCESSWIRE / November 29, 2017 / Artemis Therapeutics,
Inc. (OTCQB: ATMS), a pharmaceutical company developing new therapies for the treatment of life-threatening infectious
diseases, announced today that it will be presenting at the 10th annual LD Micro Main Event on Wednesday, December 6 at 2:30PM
PST/5:30PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Brian M. Culley, Chief Executive Officer of Artemis,
will be presenting, as well as meeting with investors.
The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 250 names
presenting to an audience of over 1,000 attendees. In addition, there will be a variety of speakers/panelists discussing topics of
interest to investors and issuers, along with coordinate evening events.
View Artemis Therapeutics' profile here: http://www.ldmicro.com/profile/ATMS.
News Compliments of ACCESSWIRE.
About Artemis Therapeutics
Artemis Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of new therapies for the
treatment and prevention of severe and life-threatening infectious diseases. The Company's lead product candidate, Artemisone, is a
unique, synthetic artemisinin derivative with potent anti-viral and anti-parasitic properties. The Company currently is evaluating
Artemisone for the treatment of p. falciparum malaria and human cytomegalovirus (CMV) infections, including stem cell
transplant CMV and congenital CMV. Artemis also plans to evaluate Artemisone for the treatment of additional viral and parasitic
diseases. More information is available on the Company's website, www.artemis-therapeutics.com, and Twitter, @ArtemisThera.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into several influential conferences annually.
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire
sector.
For those interested in attending, please contact David Scher at david@ldmicro.com or
visit www.ldmicro.com/events for more information.
Contact:
Investor Relations
ir@artemis-therapeutics.com
SOURCE: Artemis Therapeutics, Inc.
